MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
NKTX Nkarta
- 2.370
- +0.170+7.73%
Close Dec 20 16:00 ET
- 2.380
- +0.010+0.42%
Post 20:01 ET
167.25MMarket Cap-1.30P/E (TTM)
2.405High2.150Low1.92MVolume2.180Open2.200Pre Close4.44MTurnover4.78%Turnover RatioLossP/E (Static)70.57MShares16.24052wk High0.39P/B95.04MFloat Cap2.08052wk Low--Dividend TTM40.10MShs Float79.160Historical High--Div YieldTTM11.59%Amplitude1.280Historical Low2.315Avg Price1Lot Size
About Nkarta Company
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Company Profile
SymbolNKTX
Company NameNkarta
Listing DateJul 10, 2020
Issue Price18.00
Founded2005
CEOMr. Paul J. Hastings
MarketNASDAQ
Employees150
Fiscal Year Ends12-31
Address1150 Veterans Boulevard
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-925-407-1049
Websitehttp://www.nkartatx.com
Company Executives
- Name
- Position
- Salary
- Paul J. Hastings
- Chief Executive Officer and Director
- 2.93M
- Dr. Ralph Brandenberger, PhD
- Chief Technical Officer
- --
- Dr. Alicia J. Hager, PhD
- Chief Legal Officer and Corporate Secretary
- --
- Dr. David R. Shook, M.D.
- Chief Medical Officer and Head of Research and Development
- 1.51M
- Alyssa Levin
- Chief Financial Officer, Chief Business Officer and Principal Accounting Officer
- 1.29M
- Dr. Ali Behbahani, M.B.A.,M.D.
- Chairman of the Board
- 166.75K
- Dr. Nadir Mahmood, PhD
- President
- --
- Dr. Michael Dybbs, PhD
- Independent Director
- 135.25K
- Leone D Patterson
- Independent Director
- 136.25K
- Dr. Simeon J. George, M.B.A.,M.D.
- Independent Director
- 126.25K
- Angela Thedinga
- Independent Director
- 122.50K
- Dr. Zachary Scheiner, PhD
- Independent Director
- 125.25K
- George Vratsanos, M.D.
- Independent Director
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.